Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling

LING CHEN1,2, WEN-BIN ZHOU1,2, YI ZHAO1,2, XIAO-AN LIU1,2, QIANG DING1,2, XIAO-MING ZHA1,2 and SHUI WANG1,2

1Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University; 2State Key Laboratory of Reproductive Medicine, Department of Histology and Embryology, Nanjing Medical University, Nanjing, P.R. China

Received November 13, 2011; Accepted January 5, 2012

DOI: 10.3892/ijo.2012.1369

Abstract. Cancer/testis antigen (CTA) SSX2, which is silent in most normal adult tissues and expressed in various malignant tumors, has been identified for decades. Expression of SSX in tumors has been associated with advanced stages and worse patient prognosis. However, little is known about its role in breast cancer. The SSX2 expression plasmid constructed was stably transfected into the breast cancer cell line MCF-7. The influence of SSX2 on MCF-7 cells was assessed using MTT assay, flow cytometry, transwell invasion assay and in vivo tumorigenicity assay. A comparative proteomic approach was performed to identify and clarify the underlying molecular mechanisms. SSX2 expression was more pronounced in ERα-negative breast cancer cells compared with the positive ones. Overexpression of SSX2 induced cell growth and prompted cell invasion. Both ERα and E-cadherin expression were suppressed in the SSX2 overexpressing MCF-7 cells. Eleven known proteins were identified with significant differential expression. Among these, five were decreased, while other six were increased in the SSX2 overexpressing MCF-7 cells. These results suggested SSX2 may enhance invasiveness in MCF-7 cells both in vivo and in vitro. The regulation of ERα signaling by target proteins of SSX2 may explain the metastatic potential of breast cancer cells.

Introduction

Breast cancer is the most common malignancy in females worldwide. Breast cancer alone is expected to account for 28% (207,090) of all new cancer cases among American women in 2010 (1). Due to the progress of early diagnosis and systemic therapies including chemotherapy and endocrine therapy as well as targeted therapy, patients suffering from breast cancer have a better prognosis than before. However, the disease is still responsible for the second major cause of cancer-related mortality. An emerging improvement to eradicate breast cancer may be brought by cancer vaccine-based immunotherapy which should be efficient and low-toxic for patients (2). Hence, detection and identification of tumor associated antigen is of urgent need.

Cancer/testis antigens (CTAs) are a unique group of tumor antigens with normal expression restricted in the testis and in various cancers but not in adult somatic tissues (3). In some cancers, the expression of CTAs impacts a poorer prognostic future (4-8). These tissue-restricted proteins can induce spontaneous immune responses when aberrantly produced in tumors as there is no or weak central tolerance against proteins restricted to immunoprivileged sites (9). Up to now, only a few CTAs have been shown to elicit both humoral and cell-mediated immune responses in human, including SSX, MAGE-A, and NY-ESO-1 (10). MAGE-A and NY-ESO-1 are expressed in a substantial proportion of triple-negative breast cancers (11). It is also reported that SSX2 is found in breast cancer patients. These CTAs are suggested to be breast cancer antigens (12). MAGE-A3 and NY-ESO-1 as tumor targets are currently evaluated in clinical trials (13,14). However, study on SSX protein family is less advanced.

The SSX genes, located on the X chromosome, encode a family of at least ten highly homologous nuclear proteins (15). Expression of SSX proteins in tumor tissues has been associated with advanced stages and worse patient prognosis (16,17). The SSX2 gene codes for the cancer/testis antigen HOM-MEL-40 which was found to be immunologically recognized in the sera of some melanoma patients. It was expressed in approximately 20% of breast cancer samples but not in normal tissues except for testes (18). Like other members of this family, SSX2 has Krüppel-associated box (KRAB) domain and consensual sequences for N-glycosylation and tyrosine phosphorylation. In addition, the conserved C-terminus of SSX2 named as SSXRD (SSX repression domain) is associated with transcriptional repressor regulation (19,20). The SSX KRAB domain interacts with the RAB3IP (RAB3A interacting protein) and SSX2IP (SSX2 interacting protein), while the SSXRD domain interacts with LHX4 (LIM homeobox 4) and PcG protein (21,22). Current knowledge of these SSX2-interacting proteins is related to cellular growth, apoptosis and adhesion, but little is known about...
the function of SSX2 in breast cancer. Interestingly, the expression of SSX2 in malignant cells can be induced or augmented by the DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-DAC) (16). It is indicated that epigenetic molecular mechanisms in regulation of SSX2 expression could be explored as a molecular strategy in the treatment of breast cancer. Given the potential target for breast cancer vaccine-based immunotherapy, it is therefore important to elucidate the roles of SSX2 protein in breast cancer cells. With this in mind, we constructed a breast cancer cell line over-expressing SSX2 protein to investigate its effects on breast cancer.

Materials and methods

Cells, reagents, and animals. Breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-468, HCC1937, SUM1315, T47D, SK-BR-3, ZR-75-1, MCF10A, were purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in complete medium. pEGFP-C2 vector (BD Bioscience Clontech) was transfected by FuGENE™ 6 (Roche Applied Science, USA). Restriction enzymes (EcoRI/BamHI) were from New England Biolabs (USA). Antibody toward SSX2 was from Santa Cruz Biotechnology, Inc. Antibody to β-actin was from Sigma (St. Louis, MO, USA). Antibody to E-cadherin, vimentin was from Abcam (Cambridge, UK). Antibody to ERα was from Cell Signaling Technology, Inc. (Beverly, MA). Goat anti-mouse IgG-HRP and rabbit anti-goat IgG-HRP were from Santa Cruz. Balb/c null mice were from SLAC Laboratory Animal (Shanghai, China).

Vector construction. Wild-type SSX2 ORF was isolated by PCR from human testis cDNA (forward primer is 5′-GGGGAATTCCATGACGACGGCGACGCCTT-3′ and reverse primer is 5′-CGCGGATCCTCACGACCGAAGCCTC-3′). The full length of ORF is 671 bp. The fragment was cloned into pEGFP-C2 via an EcoRI/BamHI site.

Gene transfection. MCF-7 cells were transfected with pEGFP-C2-SSX2 vectors using FuGENE 6 based on a transfection reagent: DNA ratio of 3:1 according to the instruction manual. Transfection with pEGFP-C2 empty vector was used as control. After antibiotic selection (800 µg/ml G418; Sigma-Aldrich), transfectants were pooled to avoid the effects of clonal selection. After antibiotic selection (800 µg/ml G418; Sigma-Aldrich), transfectants were pooled to avoid the effects of clonal selection. Western blot analysis was performed to detect the SSX2 expression.

RT-PCR. Total RNA from cells or tissue samples was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA). The RNA was transcribed using the One Step RNA PCR Kit (AMV) from Takara Biotechnology. Specific primers for β-actin (forward, 5′-CTCCATCTGGGCTGCTGTTG-3′; reverse, 5′-GCTGTCACCTTACCGGTTCC-3′), human SSX2 (forward, 5′-GTGCTCAAAATACCGAGAACGTG-3′; reverse, 5′-TTTTGGGCTCCAGATCTTCTGGT-3′) were from Invitrogen Co. (Shanghai, China).

Western blot assay. The protein levels of SSX2, E-cadherin, vimentin, ERα in SSX2 over-expressing MCF-7 and the controls were analyzed by Western blotting using previously described methods. Primary antibodies included mouse anti-E-cadherin (clone V9), mouse anti-β-actin (clone AC-15). Secondary antibodies included goat anti-mouse IgG-HRP (1:10000) and rabbit anti-goat IgG-HRP (1:1000).

Growth curve by MTT assay. Cells (2x10^4) were grown in microtiter plates in a final volume of 180 µl complete medium per well in 37°C, 5% CO2. The growth assay was performed over a period of 6 days. After the incubation period, 20 µl of the MTT labeling reagent (0.5 mg/ml) was added to each well. The cells were analyzed by enzyme-labelled meter. The absorption was measured at 570 nm.

Apoptosis detection by flow cytometry. SSX2 over-expressing MCF-7 and the control cells were collected for apoptosis detection. The detection of apoptosis was performed according to the instruction manual of the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, San Diego, CA, USA).

Transwell invasion assay. For the transwell-based migration assay, the upper compartments of filter membranes were coated with 1 mg/ml matrigel at 4°C. SSX2 over-expressing MCF-7 and the control cells (1x10^5/well) were seeded on 8-µm pore size transwells (Corning, NY, USA). The complete medium was then added into the lower compartments of chamber. After incubated for 24 h, cell numbers were evaluated in the bottom compartment of the filter membranes. All in vitro experiments were performed in triplicates and similar results were obtained.

Tumorigenicity assay in nude mice. BALB/C nude (nu/nu) female mice (4-6-weeks old, 18-22 g) were randomly divided into two groups (each containing 10 mice). The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. A total of 5x10^6 cells suspended in 0.15 ml PBS was subcutaneously injected into the right flank of each mouse. After 8 weeks, the mice were sacrificed and the xenografts were resected, fixed in 10% buffered formalin for 6-10 h, and processed for histological analysis.

2-DE, gel image analysis and protein identification. Proteins from the two groups were extracted and separated by 2-DE. Gels were silver stained, scanned, and analyzed using ImageMaster™ 2D platinum software (Version 5.0, GE Healthcare, San Francisco, CA, USA). The expression level was determined by the relative volume of each spot in the gel and expressed as % Vol [% Vol = (spot volume/∑volumes of all spots resolved in the gel)]. Three independent experiments of cells were averaged respectively, calculated and assessed with the Student’s t-test using ImageMaster 2D platinum software. A spot was regarded differentially expressed if the change of average spot intensity was >1.5-fold and P<0.05.

Spots with significant differences were excised. Gel pieces were denatured, alkylated, trypsin digested and analyzed by an Ultraflex II MALDI-TOF-TOF mass spectrometer (Bruker Daltonics GmbH, Bremen, Germany) under the control of FlexControl™ 2.4 software (Bruker Daltonics GmbH). MALDI-TOF spectra were recorded in the positive ion reflector mode in a mass range from 700 to 4000 Da and the ion acceleration voltage was 25 kV. Acquired mass spectra were processed
using the software FlexAnalysis™ 2.4: peak detection algorithm: SNAP (sort neat assign and place); S/N threshold: 3; quality factor threshold: 50. The trypsin autodigestion ion picks [trypsin_{(108–115)}, MH^{+}842.509, trypsin_{(58–77)}, MH^{+}2211.104] were used as internal standards. Matrix and/or auto-proteolytic trypsin fragments, or known contaminant ions (keratins) were excluded. The resulting peptide mass lists were used to search the IPI human database 3.30 (67922 sequences, 28879402 residues) with Mascot (v2.1.03) in automated mode. The search criteria was as followed: significant protein Mowse score at P<0.05, minimum mass accuracy 100 ppm, trypsin as enzyme, one missed cleavage site allowed, and alkylation of cysteine by carbamidomethylation as fixed modification and oxidation of methionine as variable modification. The Mascot score and expectation of the first non-homologous protein to the highest ranked hit were checked. Protein identification was confirmed by sequence information obtained from MS/MS analysis in ‘LIFT’ (laser-induced forward transfer) mode. Acquired MS/MS spectra were also processed using the software FlexAnalysis 2.4 using a SNAP method set at an S/N threshold of 3.0. For MS/MS spectra searching, the spectra were used to search IPI human database 3.30 automated using Mascot (v2.1.03). The score was higher than the minimal significant (P<0.05) individual ion score. All significant MS/MS identifications by Mascot were manually verified for spectral quality and matching y and b ion series.

Statistical analysis. Data were analyzed by t-test for significant differences between SSX2 over-expressing MCF-7 and the control cells. All the ratios were arcsine square root transformed before t-test analysis and the least significant difference post hoc test was used to examine any significant difference between groups. The results were considered statistically significant when P<0.05.

Results

Expression of SSX2 in breast cancer cell lines. The differential mRNA expression of SSX2 was confirmed on the normal breast epithelial cell line MCF10A and a panel of 8 human breast cancer cell lines, including both non-invasive and invasive cell lines. The expression of SSX2 in human testis was performed as the positive control. The MCF10A scarcely expressed SSX2. Interestingly, ERα-negative breast cancer cell lines such as MDA-MB-231, HCC1937, SUM1315 have a higher mRNA level of SSX2, compared with ERα-positive cell lines such as MCF-7, T47D, ZR-75-1 (Fig. 1). To note, cell lines with higher mRNA levels of SSX2 were more likely to be hormone receptor-negative.

SSX2 expression involves with the growth of MCF-7 cells. For revealing the function of SSX2 on cell growth, the constructed expression vector pEFGP-C2-SSX2 was stably transfected into MCF-7 which was SSX2-negative. Both mRNA (A) and protein level (B) were confirmed.
SSX2 over-expressing cells showed a markedly decrease compared with the control cells by using MTT assay (Fig. 3). To observe the effects of SSX2 on breast cancer cell apoptosis, the detection of apoptosis by flow cytometry was performed. The over-expression of SSX2 promoted a significant increase in the early-stage apoptosis rate of MCF-7 (Fig. 4). We found that upregulation of SSX2 expression could induce early apoptosis, which indicated that SSX2 was a pro-apoptotic factor during programmed cell death of MCF-7. It was surmised that SSX2 protein was involved in breast cancer cell survival.

SSX2 expression enhances MCF-7 cell invasiveness. The invasiveness of SSX2 over-expressing MCF-7 and the control cells were assessed by transwell assays. In the transwell assay, the invasiveness through 8-µm pore transwells was significantly (P<0.05) increased in SSX2 over-expressing MCF-7, compared with the controls (Fig. 5). The average number of SSX2 over-expressing MCF-7 that migrated for 24 h was 63 cells/site, comparing with 31 cells/site for the control cells.

Over-expression of SSX2 decreases ERα and E-cadherin expression in MCF-7. The expression level of protein markers relative to MCF-7 was assessed after the transfection. As is shown in Fig. 6, ERα expression level was markedly decreased in the SSX2 over-expressing MCF-7 compared with the control cells. Interestingly, the expression level of E-cadherin was also decreased in the SSX2 over-expressing cells.

Over-expression of SSX2 prompts tumorigenesis in mice. To investigate the effect of SSX2 over-expression in vivo, we assessed tumorigenicity using SSX2 over-expressing MCF-7 and the control cells. After 8 weeks, 9/11 mice injected with SSX2 over-expressing MCF-7 showed tumors compared with 2/10 mice injected with the control cells (Fig. 7A and B). SSX2 over-expressing cells showed higher tumorigenesis in vivo. The tumor incidence was highly increased (P=0.009) in mice injected with SSX2 over-expressing MCF-7. As shown in Fig. 7C, analysis of H&E-stained tissue sections confirmed that SSX2 over-expressing MCF-7 formed abundant tumors. We examined the expression of SSX2, ERα and EMT markers in the primary tumor tissues by immunohistochemistry. As expected, SSX2 was over expressed in the SSX2 xenograft sections, while ERα expression was down-regulated. The EMT related markers showed no changes (data not shown).

Identification of altered proteins in MCF-7 after over-expression of SSX2. Since SSX2 along with its family have an acidic tail and a KRAB domain which had some relationship with transcriptional repressor activity, proteomic methods were used to identify the altered proteins in MCF-7 after over-expression of SSX2 protein. 2-DE maps of SSX2 over-expressing MCF-7 and the control cells were constructed. After spot detection,
23 protein spots were found markedly different in the SSX2 over-expressing MCF-7 compared with those in the control cells. Of all these protein spots, 10 spots increased and 13 spots decreased after over-expression of SSX2 protein. Thirteen of these protein spots were identified successfully, corresponding to 11 known proteins. The identified protein spots are shown in the 2-DE maps (Fig. 8 and Table I), while the details of 11 known proteins are in Table II.

Validation of the 2-DE results by Western blot analysis. To validate the 2-DE results, we selected five representative proteins PDIA3, ARHGDIA, HSPB1, TAGLN, TUBB2C, for the detec-
Emerging evidence has shown that auto-antibodies against CTA can be detected in primary breast cancer patients (23,24). Previous studies have demonstrated that some CTA such as MAGE and NY-ESO-1 are expressed relatively high in triple-negative breast cancer which is of limited therapeutic options (11). The SSX protein family is a potential target applicable to many types of cancer instead of tumors of a restricted histological type (25). Owing to a high frequency of expression exclusively in cancer cells, CTA can become excellent cancer-specific antigen for breast cancer diagnosis and treatment.

**Discussion**

SSX is found to be expressed in melanoma cells, fetal mesenchymal stem cells (MSCs), adult MSCs, and bone marrow. It was also observed that SSX expression is decreased
Table II. Details of 11 known altered proteins between SSX2 over-expressing MCF-7 and the control cells.

<table>
<thead>
<tr>
<th>Spot ID</th>
<th>Database</th>
<th>AC Name</th>
<th>MW</th>
<th>PI</th>
<th>Score</th>
<th>N searched</th>
<th>N matched</th>
<th>Coverage</th>
<th>S/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>1752</td>
<td>IPI</td>
<td>ALB Isoform 2 of serum albumin precursor</td>
<td>48641</td>
<td>5.97</td>
<td>5.97</td>
<td>202</td>
<td>51</td>
<td>0.53</td>
<td>&lt;1</td>
</tr>
<tr>
<td>699</td>
<td>IPI</td>
<td>ARHGDIA</td>
<td>23250</td>
<td>5.02</td>
<td>5.02</td>
<td>126</td>
<td>32</td>
<td>0.47</td>
<td>0.71</td>
</tr>
<tr>
<td>1847</td>
<td>IPI</td>
<td>PDIA3 55-kDa protein</td>
<td>25328</td>
<td>5.56</td>
<td>5.56</td>
<td>218</td>
<td>38</td>
<td>0.44</td>
<td>0.41</td>
</tr>
<tr>
<td>1513</td>
<td>IPI</td>
<td>CAPZB Isoform 1 of F-actin capping protein subunit β</td>
<td>1109</td>
<td>5.56</td>
<td>5.56</td>
<td>153</td>
<td>24</td>
<td>0.41</td>
<td>&gt;1</td>
</tr>
<tr>
<td>1274</td>
<td>IPI</td>
<td>APOA1 Apolipoprotein A-I precursor</td>
<td>20012</td>
<td>5.56</td>
<td>5.56</td>
<td>121</td>
<td>22</td>
<td>0.41</td>
<td>&gt;1</td>
</tr>
<tr>
<td>1353</td>
<td>IPI</td>
<td>PRDX6 Peroxiredoxin-6</td>
<td>20526</td>
<td>5.56</td>
<td>5.56</td>
<td>129</td>
<td>53</td>
<td>0.49</td>
<td>&lt;1</td>
</tr>
<tr>
<td>631</td>
<td>IPI</td>
<td>TAGLN Transgelin</td>
<td>22826</td>
<td>5.87</td>
<td>5.87</td>
<td>149</td>
<td>45</td>
<td>0.44</td>
<td>&lt;1</td>
</tr>
<tr>
<td>572</td>
<td>IPI</td>
<td>LDHB L-lactate dehydrogenase B chain</td>
<td>28256</td>
<td>5.56</td>
<td>5.56</td>
<td>111</td>
<td>45</td>
<td>0.55</td>
<td>&gt;1</td>
</tr>
<tr>
<td>1338</td>
<td>IPI</td>
<td>TUBB2C Tubulin β-2C chain</td>
<td>28256</td>
<td>5.87</td>
<td>5.87</td>
<td>129</td>
<td>45</td>
<td>0.44</td>
<td>&gt;1</td>
</tr>
</tbody>
</table>

S/C, % Vol ratio of SSX2 over-expressing MCF-7 to the control MCF-7. <1, after over-expression of SSX2, the protein was down-regulated. >1, after over-expression of SSX2, the protein was up-regulated.

During MSC differentiation, implicating a link between SSX expression and the processes of self-renewal and tumorigenicity (26). In our study, most triple-negative breast cancer cell lines, particularly those with a mesenchymal phenotype (MDA-MB-231, HCC1937, SUM1315), were SSX2-positive. It was implied that SSX2 was involved with invasive breast cancer cells. The differential expression between invasive and non-invasive cells adds the prerequisite for a broader application of antigen-specific immunotherapy.

Restricted expression of CTA in undifferentiated somatic and germ cells imply their essential role in embryonic development and tumor cell metastases (27). The SSX2 expression plasmid was designed and transfected into MCF-7 which is an EμRα-positive breast cancer cell line. Using the constructed stable transfected cells, we observed the effect of SSX2 on cell growth and invasion. We found that over-expression of SSX2 protein resulted in the decrease of cell proliferation and the increase of early apoptosis. Over-expression of SSX2 protein also enhanced the invasion of low invasive MCF-7 cells. These results are consistent with the differential mRNA expression between invasive and non-invasive breast cancer cell lines. Interestingly, EμRs and the epithelial marker E-cadherin expression were repressed in the SSX2 over-expressing MCF-7. However, there was no obvious change in the protein level of the mesenchymal markers such as vimentin (data not shown). MCF-7 cell tumors grow poorly without estradiol treatment in SCID mice (28,29). Our results show that SSX2 favors the growth of MCF-7 xenografts since the growth rate of tumors was roughly four times higher for SSX2 over-expressing cells when compared with the controls (i.e., 81.8 vs. 20%, respectively).

Consistently, EμRα expression was markedly down-regulated in SSX2 over-expressing MCF-7 xenografts. Previous studies verified that there is a strong positive correlation between EμRα and E-cadherin expression in human breast cancer (30). In recent years, epithelial-mesenchymal transition (EMT) has been recognized as a key step during the progression of primary tumors into metastases as well as its original role during embryogenesis (31,32). EμRs signaling through Slug regulates E-cadherin and EMT (33). In our study, consistent decrease of both the epithelial marker and EμRs suggested EMT features, which could explain the acquisitions of tumorigenesis and invasive capacity.

We performed a comparative proteomics study between SSX2 over-expressing MCF-7 and the control cells to elucidate the underlying molecular mechanisms. By comparing their peptide mass fingerprints to the IPI human database, eleven known proteins were identified and found to be a series of proteins related to proliferation, differentiation, apoptosis and cell survival (34-47). The SSX proteins are thought to act as transcriptional repressors through transcription repression domain (48). Tethering the KRAB domain to the promoter of ER target genes was able to cause suppression of gene expression (49). It has been demonstrated that binding the ligand-occupied EμRα to estrogen response elements (EREs) in DNA, the receptor interacts with multiple interactive proteins to regulate transcription of target genes. ARHGDIA also known as Rho GDP dissociation inhibitor α, is a negative regulator of the RhoGTPase family (40). It has been previously described to interact with EμRα and influence estrogen responsiveness (37). HSPB1 known as HSP27, interacts with ER and modulates ER function (41,50). In
addition, HSP27 has been recently shown to modulate p53 signaling and to suppress cellular senescence (38). In our study, decrease of ARHGDIA and HSPB1 was observed in SSX2 over-expressing MCF-7, which was consistent with down-regulation of ERα expression. There were several proteins related to invasion and migration. TAGLN (transgelin) is believed to be related to cell differentiation, cell migration, and the formation of podosomes and involved in tissue invasion and matrix remodeling (34,35,39). It has been confirmed that TAGLN is able to promote migration and invasion of CSCs (42). Microtubules are cytoskeleton that play critical roles in cell division. Their subunit protein, tubulin, is a target for various antitumor drugs such as paclitaxel and docetaxel (51,52). Alterations of β-tubulin isotypes in breast cancer cells may dictate, or predict, tumor cell behavior and responses to chemotherapeutic agents acting via the microtubule system (36). In our study, both TAGLN and TUBB2C expression were elevated in the SSX2 over-expressing group, which coincided with acquisition of invasiveness. Thus, the changing protein expression might contribute to those alternations observed after over-expression of SSX2 in MCF-7. Additional studies should help determine the potential molecular interaction between SSX2 and its target proteins.

In conclusion, we have shown for the first time that SSX2 expression was more pronounced in ERα-negative breast cancer cells compared with the positive ones. The results of the present investigation suggest that SSX2 expression may enhance invasiveness in MCF-7 cells both in vivo and in vitro. The regulation of ERα signaling and EMT process by target proteins of SSX2 may explain the metastatic potential of breast cancer cells. It may be fundamentally important in understanding the mechanisms of SSX2 in tumor progression to prompt the exploitation of immunotherapeutic interventions especially for those patients with triple-negative breast cancer.

Acknowledgements

This work was supported in part by the National Natural Science Foundation of China (81071753 and 81172502), Wu Jie-Ping Foundation (320.670010009), the Six Kinds of Outstanding Talents of Jiangsu Province (IRT-008), and a project under grant BK2009438, BK2010581, BK2011853 and BK2011855), the Health Foundation of Jiangsu Province (RC2007054), the Six Kinds of Outstanding Talents of China (81071753 and 81172502), Wu Jie-Ping Foundation (320.670010009), the Six Kinds of Outstanding Talents

References


34. Lawson D, Harrison M and Shapland C: Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 38: 250-257, 1997.


42. Dos Santos Hidalgo G, Meola J, Rosa ESJC, Paro de Paz CC and Ferriani RA: TAGLN expression is deregulated in endometriosis and may be involved in cell invasion, migration, and differentiation. Fertil Steril 96: 700-703, 2011.


